Want to join the conversation?
In 4Q15, $VRTX initiated Phase 2 clinical trial to evaluate VX-150, inhibitor of sodium channel known as NaV 1.8 involved in pain sensation, which is expected to enroll about 100 patients who have symptomatic osteoarthritis of knee. $VRTX expects to begin clinical development of VX-241, inhibitor of sodium channel known as NaV 1.7, in 1H16.
Visa ($V) set to release it earning after market close today. With new CEO resigning so close to the earnings, should we expect to see any surprises? Visa has been making strong moves with Visa Europe acquisition, partnership with PayPal and a 15% increase if quarterly dividends.
Kimberly Clark Corp ($KMB) has been in decline for most of the year, the stock has also not been getting any analyst love. Will today’s earnings break the trend? Revenue has been up and down in the last four quarters, let us see what this quarter brings.
$KMB down close to 4% after it misses on earnings and revenue. Forecasts are lower for the year.